DBV Technologies announced that patient screening is complete for the Phase 3 trial, VITESSE, using the modified Viaskin Peanut Patch in children ages 4-7 years old with peanut allergy. The fully enrolled VITESSE Phase 3 trial in peanut-allergic children ages 4-7 is a 12-month study evaluating the efficacy and safety of the Viaskin Peanut Patch in more than 600 subjects, representing individuals across 86 sites in the U.S., Canada, Europe, the UK, and Australia. VITESSE is currently the largest treatment intervention study in peanut allergy.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DBVT:
- DBV Technologies to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
- Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024
- DBV Technologies price target raised to $5 from $4 at JMP Securities
- DBV Technologies Announces Filing of 2024 Half-Year Report ― Conditions for Accessing or Consulting the Report
- DBV Technologies reports Q2 EPS (34c), consensus (45c)
Questions or Comments about the article? Write to editor@tipranks.com